1-[3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone | 400802-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone
• 英文别名: 1-[3-(4-Iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone
• CAS: 400802-89-3
• 化学式: C₁₄H₁₄IN₃O
• 分子量: 367.189
• InChiKey: ZKKKBPIMHLRNJN-UHFFFAOYSA-N

物化性质

• 沸点：
  589.1±50.0 °C(Predicted)
• 密度：
  1.688±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone 在 caesium carbonate 、 ytterbium(III) triflate 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 生成 2-(4-{3-[5-Acetyl-3-(4-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxy-propyl}-piperazin-1-yl)-benzonitrile
  参考文献：
  名称：

  Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S

  摘要：

  The first nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S (CatS) are described. Electronic database searching using the program DOCK generated a screening set of potential CatS inhibitors from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 50 nM) and selective inhibitors of CatS demonstrating cellular activity and reversibility of enzyme inhibition.

  DOI：

  10.1021/jm0496133
• 作为产物：
  描述：

  在 盐酸 、 肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-[3-(4-iodophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone
  参考文献：
  名称：

  Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S

  摘要：

  The first nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S (CatS) are described. Electronic database searching using the program DOCK generated a screening set of potential CatS inhibitors from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 50 nM) and selective inhibitors of CatS demonstrating cellular activity and reversibility of enzyme inhibition.

  DOI：

  10.1021/jm0496133

文献信息

• Method for treating allergies using substituted pyrazoles
  申请人：——

  公开号：US20030069240A1

  公开（公告）日：2003-04-10

  A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.

  使用取代吡唑烷类化合物治疗过敏症状的方法，包括特应性过敏症状。
• Substituted pyrazoles
  申请人：——

  公开号：US20020040020A1

  公开（公告）日：2002-04-04

  Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

  本文描述了替代吡唑的制造方法，包含它们的组合物，以及使用它们治疗例如由cathepsin S介导的自身免疫疾病的方法。
• Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors
  作者：Darin J. Gustin、Clark A. Sehon、Jianmei Wei、Hui Cai、Steven P. Meduna、Haripada Khatuya、Siquan Sun、Yin Gu、Wen Jiang、Robin L. Thurmond、Lars Karlsson、James P. Edwards

  DOI：10.1016/j.bmcl.2005.01.045

  日期：2005.3

  A novel series of competitive, reversible cathepsin S (Cats) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of Cats inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S. (c) 2005 Elsevier Ltd. All rights reserved.
• SUBSTITUTED PYRAZOLES
  申请人：Ortho McNeil Pharmaceuticals, Inc.

  公开号：EP1309591A2

  公开（公告）日：2003-05-14
• METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES
  申请人：Ortho McNeil Pharmaceuticals, Inc.

  公开号：EP1315491A2

  公开（公告）日：2003-06-04